GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » YoY Rev. per Sh. Growth

CNBX (CNBX Pharmaceuticals) YoY Rev. per Sh. Growth : -100.00% (As of Nov. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. CNBX Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Nov. 2024 was -100.00%.

CNBX Pharmaceuticals's Revenue per Share for the three months ended in Nov. 2024 was $0.00.


CNBX Pharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for CNBX Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals YoY Rev. per Sh. Growth Chart

CNBX Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.33 -100.00 - 84.00 -91.30

CNBX Pharmaceuticals Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -100.00 -100.00 -100.00

CNBX Pharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

CNBX Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Aug. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Aug. 2024 )
=(Revenue per Share (A: Aug. 2024 )-Revenue per Share (A: Aug. 2023 ))/ | Revenue per Share (A: Aug. 2023 ) |
=(0.004-0.046)/ | 0.046 |
=-91.30 %

CNBX Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Nov. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Nov. 2024 )
=(Revenue per Share (Q: Nov. 2024 )-Revenue per Share (Q: Nov. 2023 )) / | Revenue per Share (Q: Nov. 2023 )) |
=(0-0.003)/ | 0.003 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary